@filipe_rafaeli
The key proposition on the table is this: HCQ + AZM +/- Zn, administered just as soon as symptoms arise, greatly reduces need for subsequent hospitalization and risk of death.
The key proposition on the table is this: HCQ + AZM +/- Zn, administered just as soon as symptoms arise, greatly reduces need for subsequent hospitalization and risk of death.
I have aggregated all reported large case series I can find evaluating this protocol (including those in Table 1 of Dr. Risch's new letter: pubmed.ncbi.nlm.nih.gov/32685966/) - many focusing on high-risk patients.
I calculate a case-fatality rate of about 0.4% - one-tenth that of Germany (4%). The latter is a good comparator, since Germany tests extensively (lowering the CFR), and has first-rate supportive care - but HCQ use is minimal. Case-series from physicians on 3 continents.
It may be that some docs with mediocre results with this regimen simply haven't spoken up. But I have never heard of ANY doc who has used this regimen on a large number of patients and has had disappointing results. So this 0.4% surely MEANS something, something big.
Yet academic physicians call this all "anecdotal", and demand a "gold standard" placebo-controlled RCT. Well, the NIH commenced just such a study on early HCQ/AZM in May - then discontinued it a month later owing to paltry enrollment (20 patients).
niaid.nih.gov/news-events/bu…
niaid.nih.gov/news-events/bu…
Dr. Zelenko's small clinic has managed to treat 805 high-risk patients so far - but a multi-center US trial managed to enroll only 20 patients in over a month. Criminal incompetence.
Yet did those insisting on a "gold standard" study protest vociferously when this key study was cancelled? I heard nary a peep from them. This shows that they are either willfully, grossly ignorant of the evidence - or they are outright frauds.
@threadreaderapp unroll
